Learn about DARZALEX FASPRO® + VRd, the latest FDA-approved quad treatment combination for people with newly diagnosed multiple myeloma who are not eligible to receive a stem cell transplant

Sign Up For Support

DARZALEX FASPRO ® is now FDA approved as the first therapy for use alone to treat adults with high-risk smoldering multiple myeloma.

Homepage Banner Desktop Image
Starting TreatmentDARZALEX FASPRO® and DARZALEX® Clinical Trial Results

DARZALEX FASPRO® and DARZALEX® clinical trial results

DARZALEX FASPRO® and DARZALEX® are used with other medicines or by themselves depending on your treatment plan.

Treatment combinations

Find out more about a

quad combination treatment

One possible treatment combination is DARZALEX FASPRO® + VRd (bortezomib (V) + lenalidomide (R) + dexamethasone (d)), which is known as a quadruplet (quad) therapy, and consists of 4 treatments.

Learn more

Find out more about a

triplet combination treatment

DARZALEX® was also studied as a triplet therapy. It was combined with Rd (lenalidomide (R) + dexamethasone (d)) in this triplet treatment study.

Learn more

Find out more about

additional clinical studies

Discover additional clinical study evidence for other DARZALEX FASPRO®- and DARZALEX®-based treatment regimens

Learn more

Find out more about

high-risk smoldering multiple myeloma

Discover DARZALEX FASPRO® for people with high-risk smoldering multiple myeloma

Learn more
NextDARZALEX FASPRO® + VRd Treatment Results